{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:09:32Z","timestamp":1761548972715,"version":"build-2065373602"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2008,11,14]],"date-time":"2008-11-14T00:00:00Z","timestamp":1226620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2008,11,14]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Tumor necrosis factor alpha (TNF-\u03b1 ) therapy has been implicated in the development of autoimmune diseases. Our aim was to describe three patients with spondyloarthropathies who responded to infliximab, a chimeric monoclonal antibody specific for TNF-\u03b1  but developed new symptoms of spondyloarthropathies. In parallel, a review of the literature on psoriasis induced by TNF-\u03b1  blockers was undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The first patient had been suffering from ankylosing spondylitis (AS) for more than 12 years. Infliximab induced a remission of AS, but he developed overt Crohn's disease two years after starting treatment. The second patient had AS for more than 20 years. Infliximab had an excellent effect on his AS, but he developed palmo-plantar psoriasis a few months after initiating therapy with the drug. The third patient, whose long-term and severe psoriasis had responded to infliximab developed peripheral arthritis. A review of the literature revealed 63 cases of psoriasis induced by TNF-\u03b1  blockers (33 on Infliximab, 16 on Etanercept and 14 on Adalimumab). The underlying diseases were variable, including all the spectrum of conditions for which TNF-\u03b1  blockers are indicated. Patients developed psoriasis after a mean duration of treatment of 11 months. Interstingly, a substantial proportion of patients continued treatment with TNF \u03b1 blockers, the psoriasis improving in a majorityof cases under topical treatment only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While Infliximab may change the course of spondyloarthropathy, depressing the original symptoms it may uncover other occult aspects of these diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1874312900802010053","type":"journal-article","created":{"date-parts":[[2008,11,18]],"date-time":"2008-11-18T12:16:29Z","timestamp":1227010589000},"page":"53-57","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Changing Face of Spondyloarthropathies Under TNF \u03b1  Blockade"],"prefix":"10.2174","volume":"2","author":[{"given":"Ori","family":"Elkayam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Litinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Levartovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1186\/ar552","volume":"4","author":"Kalden JR","year":"2002","unstructured":"Kalden JR. \n                Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases \n                Arthritis Res  \n                2002; \n                4\n                (2)\n                : S34-40.","journal-title":"Arthritis Res"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"Ramos-Casals M","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer NP, Munoz S, et al. \n                Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 Cases \n                Medicine Baltimore  \n                2007; \n                86\n                : 242-51.","journal-title":"Medicine Baltimore"},{"key":"refR3","first-page":"223","volume":"143","author":"De Gannes GC","year":"2007","unstructured":"De Gannes GC, Ghoreishi M, Pope J, et al. \n                Psoriasis and pustular dermatitis triggered by TNF-\u03b1inhibitors in patients with rheumatologic conditions \n                Arch Dermatol  \n                2007; \n                143\n                : 223-31.","journal-title":"Arch Dermatol"},{"unstructured":"Wright V, Moll JMH. \n                Seronegative polyarthritis. \n                Amsterdam New York, Oxford: North Holland Publishing Company 1976.","key":"refR4"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archderm.143.2.270","volume":"143","author":"Ubriani R","year":"2007","unstructured":"Ubriani R, Van Voorhees AS. \n                Onset of psoriasis during treatment with TNF-a antagonists: a report of 3cases \n                Arch Dermatol  \n                2007; \n                143\n                (2)\n                : 270-.","journal-title":"Arch Dermatol"},{"key":"refR6","first-page":"380","volume":"34","author":"Cohen JD","year":"2007","unstructured":"Cohen JD, Bournerias I, Buffard V, et al. \n                Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series \n                J Rheumatol  \n                2007; \n                34\n                (2)\n                : 380-5.","journal-title":"J Rheumatol"},{"key":"refR7","first-page":"1411","volume":"33","author":"Sari I","year":"2006","unstructured":"Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. \n                Anti-tumor necrosis factor-alpha-induced psoriasis \n                J Rheumatol  \n                2006; \n                33\n                (7)\n                : 1411-4.","journal-title":"J Rheumatol"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","volume":"38","author":"Verea MM","year":"2004","unstructured":"Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. \n                Psoriasiform eruption induced by infliximab \n                Ann Pharmacother  \n                2004; \n                38\n                (1)\n                : 54-7.","journal-title":"Ann Pharmacother"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.20155","volume":"50","author":"Beuthien W","year":"2004","unstructured":"Beuthien W, Mellinghoff HU, Von Kempis J. \n                Skin reaction to adalimumab \n                Arthritis Rheum  \n                2004; \n                50\n                (5)\n                : 1690-2.","journal-title":"Arthritis Rheum"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"Sfikakis PP","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglu A, Kittas C, Stratigos A. \n                Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction \n                Arthritis Rheum  \n                2005; \n                52\n                : 2513-8.","journal-title":"Arthritis Rheum"},{"key":"refR11","first-page":"247","volume":"34","author":"Roux CH","year":"2007","unstructured":"Roux CH, Brocq O, Leccia N, et al. \n                New-onset psoriatic palmoplantaris pustulosis following infliximab therapy a class effect? \n                J Rheumatol  \n                2007; \n                34\n                : 247-9.","journal-title":"J Rheumatol"},{"key":"refR12","first-page":"178","volume":"5","author":"Adams DR","year":"2006","unstructured":"Adams DR, Buckel T, Sceppa JA. \n                Infliximab-associated new-onset psoriasis \n                J Drugs Dermatol  \n                2006; \n                5\n                : 178-9.","journal-title":"J Drugs Dermatol"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","volume":"151","author":"Dereure O","year":"2004","unstructured":"Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. \n                Psoriatic lesions induced by anti-tumor necrosis factor-alpha treatment: two cases \n                Br J Dermatol  \n                2004; \n                151\n                : 506-7.","journal-title":"Br J Dermatol"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/ar1724","volume":"7","author":"Flendrie M","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, Van Riel PL. \n                Dermatological conditions during TNF-\u03b1 -blocking therapy in patients with rheumatoid arthritis: a prospective study \n                Arthritis Res Ther  \n                2005; \n                7\n                : 666-76.","journal-title":"Arthritis Res Ther"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/art.20954","volume":"52","author":"Grinblat B","year":"2005","unstructured":"Grinblat B, Scheinberg M. \n                Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien \n                Arthritis Rheum  \n                2005; \n                52\n                (4)\n                : 1333-4.","journal-title":"Arthritis Rheum"},{"key":"refR16","first-page":"405","author":"Haibel H","year":"2004","unstructured":"Haibel H, Spiller I, Strasser C. \n                Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNF-\u03b1 blocking agents [abstract] \n                Ann Rheum Dis  \n                2004; \n                (63)\n                405.","journal-title":"Ann Rheum Dis"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","volume":"65","author":"Kary S","year":"2006","unstructured":"Kary S, Worm M, Audring H, et al. \n                New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumor necrosis factor alpha antagonists \n                Ann Rheum Dis  \n                2006; \n                65\n                : 405-7.","journal-title":"Ann Rheum Dis"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","volume":"153","author":"Michaelsson G","year":"2005","unstructured":"Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. \n                Infliximab can precipitate as well as worsen palmoplantar pustulosis possible linkage to the expression of tumor necrosis factor-alpha in the normal palmar eccrine sweat duct? \n                Br J Dermatol  \n                2005; \n                153\n                : 1243-4.","journal-title":"Br J Dermatol"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2230.2005.01882.x","volume":"30","author":"Peramiquel L","year":"2005","unstructured":"Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. \n                Onset of flexural psoriasis during infliximab treatment for Crohn's disease \n                Clin Exp Dermatol  \n                2005; \n                30\n                : 713-4.","journal-title":"Clin Exp Dermatol"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00296-004-0567-5","volume":"25","author":"Starmans-Kool MJ","year":"2005","unstructured":"Starmans-Kool MJ, Peeters HR, Houben HH. \n                Pustular skin lesions in patients treated with infliximab: report of two cases \n                Rheumatol Int  \n                2005; \n                25\n                : 550-2.","journal-title":"Rheumatol Int"},{"key":"refR21","first-page":"439","volume":"3","author":"Thurber M","year":"2004","unstructured":"Thurber M, Feasel A, Stroehlein J, Hymes SR. \n                Pustular psoriasis induced by infliximab \n                J Drugs Dermatol  \n                2004; \n                3\n                : 439-0.","journal-title":"J Drugs Dermatol"},{"key":"refR22","first-page":"438","volume":"34","author":"Richette P","year":"2007","unstructured":"Richette P, Viguier M, Bachelez H, Bardin T. \n                Psoriasis induced by anti-tumor necrosis factor therapy: a class effect? \n                J Rheumatol  \n                2007; \n                34\n                (2)\n                : 438-9.","journal-title":"J Rheumatol"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2230.2006.02315.x","volume":"32","author":"Goiriz R","year":"2006","unstructured":"Goiriz R, Dauden E, Perez-Gala G, Guhl G, Garcia-Diez A. \n                Flare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockers \n                Clin Exp Dermatol  \n                2006; \n                32\n                : 176-9.","journal-title":"Clin Exp Dermatol"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0151-9638(07)89192-7","volume":"134","author":"Cavailhes A","year":"2007","unstructured":"Cavailhes A, Ingen-Housz-Oro S, Djennane S, et al. \n                Survenue d'un psoriasis au cours d'un treatement par infliximab pour fasciite de Shulman \n                Ann Dermatol Venereol  \n                2007; \n                134\n                (4 Pt 1)\n                : 363-7.","journal-title":"Ann Dermatol Venereol"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00296-006-0144-1","volume":"26","author":"Volpe A","year":"2006","unstructured":"Volpe A, Caramaschi P, Carletto A, Pieropan S, Bambara LM, Biasi D. \n                Psoriasis onset during infliximab treatment: description of two cases \n                Rheumatol Int  \n                2006; \n                26\n                : 1158-60.","journal-title":"Rheumatol Int"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1468-3083.2006.01979.x","volume":"21","author":"Papadavid E","year":"2007","unstructured":"Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelia V. \n                Palmoplantar and scalp psoriasis occurring during anti-tumor necrosis factor a therapy: a case series of four patients and guidelines for management \n                J Eur Acad Dermatol Venerol  \n                2007; \n                21\n                : 380-2.","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1468-3083.2007.02230.x","volume":"21","author":"Martinez-Moran C","year":"2007","unstructured":"Martinez-Moran C, Sanz-Munoz C, Morales-Callaghan AM, Torrero V, Miranda-Romero A. \n                Pustular psoriasis induced by infliximab \n                J Eur Acad Dermatol Venerol  \n                2007; \n                21\n                : 1413-50.","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1346-8138.2007.00312.x","volume":"34","author":"Takahashi H","year":"2007","unstructured":"Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. \n                Psoriasiform and pustular eruption induced by infliximab \n                J Dermatol  \n                2007; \n                34\n                (7)\n                : 468-72.","journal-title":"J Dermatol"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.eye.6702262","volume":"21","author":"Wegscheider BJ","year":"2007","unstructured":"Wegscheider BJ, El-Shabrawi L, Weger M, et al. \n                Adverse skin reactions to infliximab in the treatment of intraocular inflammation \n                Eye  \n                2007; \n                21\n                : 547-9.","journal-title":"Eye"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2005.049916","volume":"65","author":"Peek R","year":"2006","unstructured":"Peek R, Scott-Jupp R, Strike H, Clinch J, Ramanan AV. \n                Psoriasis after treatment of juvenile idiopathic arthritis with etanercept \n                Ann Rheum Dis  \n                2006; \n                65\n                (9)\n                : 1259.","journal-title":"Ann Rheum Dis"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08916930400021378","volume":"38","author":"Elkayam O","year":"2005","unstructured":"Elkayam O, Burke M, Vardinon N, et al. \n                Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab \n                Autoimmunity  \n                2005; \n                38\n                : 155-60.","journal-title":"Autoimmunity"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"Eriksson C","year":"2005","unstructured":"Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. \n                Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-\u03b1 \n                Ann Rheum Dis  \n                2005; \n                64\n                : 403-7.","journal-title":"Ann Rheum Dis"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"De Rycke L","year":"2003","unstructured":"De Rycke L, Kruithof E, Van Damme N, et al. \n                Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy \n                Arthritis Rheum  \n                2003; \n                48\n                : 1015-23.","journal-title":"Arthritis Rheum"},{"key":"refR34","first-page":"1542","volume":"18","author":"Mielants H","year":"1991","unstructured":"Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M. \n                Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology A prospective study \n                J Rheumatol  \n                1991; \n                18\n                : 1542-51.","journal-title":"J Rheumatol"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.dld.2005.04.028","volume":"37","author":"Conti F","year":"2005","unstructured":"Conti F, Borrelli O, Anania C, et al. \n                Chronic intestinal inflammation and seronegative spondyloarthropathy in children \n                Dig Liver Dis  \n                2005; \n                37\n                : 761-.","journal-title":"Dig Liver Dis"},{"key":"refR36","first-page":"203","volume":"39","author":"Ruemmele FM","year":"2004","unstructured":"Ruemmele FM, Prieur AM, Talbotec C, et al. \n                Development of Crohn disease during anti-TNF-\u03b1 therapy in a child with juvenile idiopathic arthritis \n                J Pediatr Gastroenterol Nutr  \n                2004; \n                39\n                : 203-6.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"refR37","first-page":"52","volume":"32","author":"Oh J","year":"2005","unstructured":"Oh J, Arkfeld DG, Horwitz DA. \n                Development of Crohn's disease in a patient taking etanercept \n                J Rheumatol  \n                2005; \n                32\n                : 52-3.","journal-title":"J Rheumatol"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2133.2007.08009.x","volume":"157","author":"Ahmad K","year":"2007","unstructured":"Ahmad K, Rogers S. \n                Development of Crohn disease in a patient on etanercept for psoriasis \n                Br J Dermatol  \n                2007; \n                157\n                (2)\n                : 396.","journal-title":"Br J Dermatol"},{"key":"refR39","first-page":"532","volume":"35","author":"Song IH","year":"2008","unstructured":"Song IH, Appel H, Haibel H, et al. \n                New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept \n                J Rheumatol  \n                2008; \n                35\n                (3)\n                : 532-6.","journal-title":"J Rheumatol"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","volume":"153","author":"Michaelsson G","year":"2005","unstructured":"Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. \n                Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor-alpha in the normal palmar eccrine sweat duct? \n                Br J Dermatol  \n                2005; \n                153\n                : 1243-4.","journal-title":"Br J Dermatol"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","volume":"140","author":"Gilliet M","year":"2004","unstructured":"Gilliet M, Conrad C, Geiges M, et al. \n                Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors \n                Arch Dermatol  \n                2004; \n                140\n                : 1490-5.","journal-title":"Arch Dermatol"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.berh.2006.08.010","volume":"20","author":"Strangfeld A","year":"2006","unstructured":"Strangfeld A, Listing J. \n                Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy \n                Best Pract Res Clin Rheumatol  \n                2006; \n                20\n                : 1181-95.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1566524043479347","volume":"4","author":"Breban M","year":"2004","unstructured":"Breban M, Hacquard-Bouder C, Falgarone G. \n                Animal models of HLA-B27-associated diseases \n                Curr Mol Med  \n                2004; \n                4\n                : 31-40.","journal-title":"Curr Mol Med"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/01.bor.0000163447.44037.c4","volume":"17","author":"Kim TH","year":"2005","unstructured":"Kim TH, Uhm WS, Inman RD. \n                Pathogenesis of ankylosing spondylitis and reactive arthritis \n                Curr Opin Rheumatol  \n                2005; \n                17\n                : 400-5.","journal-title":"Curr Opin Rheumatol"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/path.1044","volume":"196","author":"Baeten D","year":"2002","unstructured":"Baeten D, Demetter P, Cuvelier CA, et al. \n                Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy \n                J Pathol  \n                2002; \n                196\n                : 343-50.","journal-title":"J Pathol"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/1529-0131(200104)44:4<931::AID-ANR150>3.0.CO;2-T","volume":"44","author":"Seta N","year":"2001","unstructured":"Seta N, Granfors K, Sahly H, et al. \n                Expression of the host defence scavenger receptors in spondyloarthropathy \n                Arthritis Rheum  \n                2001; \n                44\n                : 931-.","journal-title":"Arthritis Rheum"}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V2\/TORJ-2-53\/TORJ-2-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V2\/TORJ-2-53\/TORJ-2-53.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V2\/TORJ-2-53\/TORJ-2-53.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:00:52Z","timestamp":1761548452000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/2\/PAGE\/53\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,14]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,11,14]]}},"alternative-id":["TORJ-2-53"],"URL":"https:\/\/doi.org\/10.2174\/1874312900802010053","relation":{},"ISSN":["1874-3129"],"issn-type":[{"type":"print","value":"1874-3129"}],"subject":[],"published":{"date-parts":[[2008,11,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2008-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-03-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}